AOD-9604 Peptide: Complete Research Guide

At a glance: AOD-9604 peptide research summary

AOD 9604 (Advanced Obesity Drug 9604) is a synthetic peptide derivatized from the lipolytic C-terminal region of human growth hormone (hGH 177–191) with an added C-terminal tyrosine residue. Designed to isolate hGH's fat-metabolizing actions from its anabolic and diabetogenic signaling, AOD 9604 is a primary reference compound in preclinical metabolic research.

Preclinical and in vitro investigations demonstrate that the AOD 9604 peptide stimulates beta-3 adrenergic receptors and enhances lipolysis in isolated adipocytes without elevating circulating IGF-1 or impairing glucose tolerance. These distinct characteristics make it a critical reagent for studies evaluating lipid oxidation, body composition regulation, and cartilage tissue dynamics.

Researchers seeking reproducible assay outcomes rely on verified peptide identity and purity. PX1 Research provides fully characterized lyophilized AOD 9604 accompanied by public, lot-tracked analytical reports to ensure strict experimental control across all laboratory workflows.

What is AOD-9604 peptide?

AOD 9604 is a hexadecapeptide with the primary amino acid sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe. It represents a modified fragment of the human growth hormone molecule, specifically corresponding to amino acids 177 through 191, with an additional N-terminal tyrosine residue added to stabilize the peptide structure.

Originally synthesized to map the active domain responsible for growth hormone's lipid-mobilizing properties, the fragment was isolated to exclude regions that trigger systemic growth, tissue hyperplasia, or insulin resistance. Unlike full-length hGH (191 amino acids), the C-terminal fragment operates independently of growth hormone receptors, focusing its action on adipose tissue signaling cascades.

In modern laboratory protocols, researchers buy AOD 9604 to study lipid enzyme regulation, adipocyte apoptosis pathways, and extracellular matrix preservation in chondrocyte assays without confounding systemic hormonal cascades.

How does AOD-9604 function in metabolic pathways?

The cellular mechanism of AOD 9604 centers on the stimulation of lipolysis (fat breakdown) and the inhibition of lipogenesis (fat accumulation). In vitro research on rodent and human adipocyte cultures indicates that the peptide binds to specific non-GH receptor sites on fat cell membranes, upregulating intracellular cyclic adenosine monophosphate (cAMP) levels.

This elevation of cAMP activates hormone-sensitive lipase (HSL), the key enzyme responsible for hydrolyzing stored triglycerides into free fatty acids and glycerol. Concurrently, preclinical data suggest AOD 9604 reduces acetyl-CoA carboxylase activity, thereby attenuating de novo fatty acid synthesis within white adipose tissue.

Importantly, because AOD 9604 lacks the N-terminal sequence of intact hGH required for growth hormone receptor dimer formation, it does not induce IGF-1 gene expression in hepatic tissues. This functional separation allows researchers to isolate lipolytic metabolic pathways from proliferative endocrine signaling.

What do preclinical anti-obesity and cartilage studies show?

Preclinical trials in obese animal models (such as ob/ob mice and Zucker diabetic fatty rats) demonstrate that sustained administration of AOD 9604 results in significant reductions in total body fat mass. The peptide selectively targets visceral and subcutaneous adipose depots while preserving lean muscle mass and organ weight.

Unlike classic growth hormone secretagogues or full-length recombinant hGH, AOD 9604 does not induce hyperinsulinemia or glucose intolerance in long-term rodent models. Fasting blood glucose, insulin sensitivity markers, and oral glucose tolerance tests remain unaffected during treatment periods, highlighting its neutral glycemic profile in laboratory settings.

In addition to fat metabolism, emerging research evaluates AOD 9604 in musculoskeletal models. In vitro chondrocyte cultures and animal joint injury models show that AOD 9604 may enhance proteoglycan synthesis and cartilage matrix restoration when co-administered with hyaluronic acid, opening new avenues for joint degeneration research.

How does AOD-9604 compare to intact hGH and growth hormone secretagogues?

To select the correct compound for specific research hypotheses, investigators must evaluate how AOD 9604 differs from full-length hGH and secretagogues like CJC-1295 or Ipamorelin. The primary distinction lies in receptor binding selectivity and systemic metabolic impact.

While full-length hGH triggers multi-system effects including skeletal growth, liver IGF-1 release, fluid retention, and altered glucose utilization, AOD 9604 acts strictly on lipid mobilization pathways without interacting with the classic growth hormone receptor. Similarly, ghrelin receptor agonists like Ipamorelin stimulate endogenous pituitary hGH release, creating a systemic hormonal pulse rather than targeted adipocyte action.

Researchers studying broad pituitary axis dynamics often utilize our catalog of research peptides to source secretagogues, whereas those focusing specifically on isolated lipid kinetics or non-IGF-1 mediated metabolic pathways select targeted fragments like AOD 9604.

How to evaluate an AOD-9604 supplier: Red flags to avoid

Because AOD 9604 contains a disulfide bridge between Cys7 and Cys14, proper folding and synthesis are critical. Substandard synthesis leads to mismatched disulfide bonds, inactive stereoisomers, or unstable peptide aggregates. Evaluating supplier quality requires strict analytical scrutiny.

Red flags when vetting research peptide suppliers include:

1. Lack of lot-specific Certificate of Analysis (COA): Suppliers providing static, template, or outdated COAs without lot number matching are untrustworthy.

2. HPLC without MS integration: Mass Spectrometry (MS) is mandatory to verify exact molecular weight (1815.1 Da). High-Performance Liquid Chromatography (HPLC) alone only measures purity percentage, not sequence identity.

3. Missing endotoxin testing: Bacterial endotoxins (LPS) cause severe inflammatory responses in cellular assays, rendering cell culture data invalid.

4. Non-standard lyophilization: Vials that arrive as sticky liquids or discolored cakes indicate inadequate moisture control or thermal degradation during storage.

5. Consumer or medical claims: Vendors selling peptides with human dosing instructions or therapeutic guarantees operate outside lawful research supplier frameworks and frequently compromise on analytical quality.

PX1 Research verification vs standard vendor standards

PX1 Research enforces rigid quality control metrics for every lot of AOD 9604 10 mg. Below is a direct comparison of our quality benchmarks against industry norms:

• Purity Verification: Standard vendors offer single-wavelength HPLC showing ~95% purity. PX1 Research guarantees ≥98% purity confirmed via dual-wavelength HPLC and electrospray ionization mass spectrometry (ESI-MS).

• Molecular Identity: Standard vendors rarely supply MS mass spectra. PX1 Research includes full MS spectra matching the exact monoisotopic mass of AOD 9604 for every batch.

• Endotoxin Control: Standard vendors omit endotoxin testing entirely. PX1 Research conducts Chromogenic LAL testing to ensure endotoxin levels remain below strictly controlled limits (<0.01 EU/mg).

• Traceability & Transparency: Standard vendors provide non-downloadable COAs or blur lot numbers. PX1 Research publishes full, unredacted, third-party laboratory reports indexed by lot number on our website.

• Logistics & Stability: Standard vendors ship via low-tier postal services with long transit times. PX1 Research dispatches directly from cold-chain monitored facilities in California and Arizona with same-day fulfillment on orders placed before 3 PM EST.

Laboratory reconstitution and handling guidelines

AOD 9604 is supplied as a sterile, lyophilized white powder in sealed glass vials. To maintain structural integrity and biological activity in laboratory assays, precise handling protocols must be observed.

Reconstitution should be conducted using bacteriostatic water or sterile phosphate-buffered saline (PBS, pH 7.4) depending on assay requirements. Due to the hydrophobic nature of certain residues in the C-terminal fragment, gentle swirl agitation is recommended—never vortex or vigorously shake the reconstituted solution, as shear stress can cause peptide denaturation or aggregation.

Once reconstituted, stock solutions should be aliquot-divided into sterile microcentrifuge tubes to prevent repeated freeze-thaw cycles. Short-term storage of reconstituted liquid should be kept at 2°C to 8°C for no more than 14 days, while lyophilized vials remain stable at -20°C for up to 24 months. Review our detailed peptide research documentation for complete storage parameters.

Ordering AOD-9604 from PX1 Research

When your laboratory requires analytical-grade AOD 9604 for metabolic or cellular research, PX1 Research provides seamless ordering, transparent documentation, and fast fulfillment. Each unit ships as a vacuum-sealed vial containing high-purity lyophilized peptide packaged to withstand ambient transit temperatures.

Orders placed Monday through Friday prior to 3 PM EST are processed and shipped same-day from our dual distribution hubs in Arizona and California, ensuring rapid domestic arrival with complete tracking transparency. Every package includes direct QR code access to your specific lot's analytical COA, including HPLC chromatograms, mass spectrometry curves, and endotoxin reports.

Whether executing pilot cellular assays or high-throughput animal studies, explore our complete selection or order 10 mg vials of AOD-9604 today with total confidence in chemical consistency.